Intravitreal (IVT) administration of anti-vascular endothelial growth factor (VEGF) therapy is currently the preferred treatment strategy for vascular retinal diseases, such as neovascular AMD (wet AMD), diabetic retinopathy, and diabetic macular edema.1 This evidence concerns the gene VEGFA and wet macular degeneration.